Corbus Pharmaceuticals Holdings, Inc. announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors. This marks a significant expansion of the CRB-701 clinical program, exploring its potential in combination with Keytruda (pembrolizumab), a widely used immune checkpoint inhibitor. Participants in this arm are being randomized to 2.7 mg/kg and 3.6 mg/kg cohorts.
The Phase 1 Western study (NCT06265727) is evaluating the safety, pharmacokinetics, and efficacy of CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors. Previous data for CRB-701 has demonstrated differentiated safety, tolerability, and efficacy profiles in head and neck squamous cell carcinoma (HNSCC), cervical, and metastatic urothelial carcinoma (mUC) tumors.
Exploring CRB-701 in combination with pembrolizumab aims to leverage potential synergistic effects, a common strategy in oncology to enhance anti-tumor activity. The company expects to provide a data update and establish the recommended Phase 2 dose (RP2D) for CRB-701 in the fourth quarter of 2025. This advancement underscores Corbus's strategy to maximize the value of its oncology assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.